Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Hope against dangerous form of acute lymphoblastic leukemia

After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer-the first time anyone has linked the disease's reemergence to specific genetic anomalies.

4 Feb 2013

Mcl-1 gene essential for survival of antibody-producing cells

Scientists have identified the gene essential for survival of antibody-producing cells, a finding that could lead to better treatments for diseases where these cells are out of control, such as myeloma and chronic immune disorders.

3 Feb 2013

Dairy intake may increase risk of bone mineral density in the hip

A study by researchers at the Institute for Aging Research (IFAR) at Hebrew SeniorLife, an affiliate of Harvard Medical School (HMS), has found that dairy intake -specifically milk and yogurt -is associated with higher bone mineral density (BMD) in the hip, but not the spine.

1 Feb 2013

Innate lymphoid cells may be new therapeutic target in treating atopic dermatitis

The increasing incidence of allergic skin diseases, and the accompanying economic burden and heightened risk of developing other allergic conditions, have spurred researchers to look for better ways to control these immune system-based disorders.

1 Feb 2013

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM, its new intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency (PI).

31 Jan 2013

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

31 Jan 2013

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech, a member of the Roche Group, today announced positive results from Stage 1 of CLL11, a Phase III randomized study to investigate the efficacy and safety profile of the investigational medicine obinutuzumab (GA101) plus chlorambucil chemotherapy compared with chlorambucil alone in people with previously untreated chronic lymphocytic leukemia (CLL).

31 Jan 2013

New noninvasive method for early detection of osteoarthritis may be on its way

A new, noninvasive, and low-cost method for the early detection and monitoring of osteoarthritis (arthritis caused by wear and tear) may be on its way, thanks to research by UC Santa Barbara scientists from the Department of Chemical Engineering and the Department of Materials.

31 Jan 2013

Supplementation with omega-3 fatty acids promotes effective immune system response

Supplementation with omega-3 fatty acids promotes effective immune system response and has ameliorating effects on chronic inflammation (a condition caused by an imbalanced immune system that can lead to multiple serious illnesses over time), according to the most recent study published by the National Center for Biotechnology Information on the effects of omega-3.

31 Jan 2013

Mount Sinai to initiate immunological therapy trial against chronic pulmonary sarcoidosis

Patients are currently being enrolled in the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis. The trial is being conducted by researchers at the Icahn School of Medicine at Mount Sinai.

31 Jan 2013

Report calls for greater emphasis on preventive care

A report issued by the Trust for America's Health is urging a revamp of state and local public health efforts to better integrate and focus prevention strategies.

30 Jan 2013

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Merck Serono, a division of Merck, Darmstadt, Germany, and The Feinstein Institute for Medical Research, announced today that they will collaborate to develop antibodies for the treatment of systemic lupus erythematosus (SLE).

30 Jan 2013

Glenmark third quarter consolidated revenue increases 33.96% to Rs. 13812.59M

Glenmark Pharmaceuticals Limited (GPL), the research-led global integrated pharmaceutical company announced its results for the third quarter ended December 31, 2012.

30 Jan 2013

Tofacitinib fights rheumatoid arthritis progression

Tofacitinib treats symptoms and prevents structural damage in patients with rheumatoid arthritis who do not respond well to methotrexate, indicate phase III trial findings.

29 Jan 2013

Childhood adversity raises comorbidity risk in bipolar disorder

Childhood adversity, including verbal, physical, or sexual abuse, is associated with the later development of multiple medical comorbidities in patients with bipolar disorder, researchers report.

29 Jan 2013

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

29 Jan 2013

Hypertensive pregnancies need rigorous follow up

Women who have hypertensive complications during pregnancy are at increased risk for developing chronic kidney disease and end-stage renal disease, shows a study in the Canadian Medical Association Journal.

28 Jan 2013

Immunosuppressive drugs do not increase risk of cancer in lupus patients

People who take immunosuppressive drugs to treat lupus do not necessarily increase their cancer risk according to new research led by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC).

28 Jan 2013

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

The U. S. Patent and Trademark Office recently issued a patent to the U. S. Department of Health and Human Services involving resiniferatoxin, or RTX, an experimental compound that represents a potential new class of drugs to alleviate the intractable pain that can occur in people with advanced cancer, severe arthritis, and other extremely chronic conditions.

28 Jan 2013

FDA accepts Genzyme’s LEMTRADA sBLA for review

Genzyme, a Sanofi Company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental Biologics License Application (sBLA) file seeking approval of LEMTRADA (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS).

28 Jan 2013